News | Stroke | July 12, 2017

SanBio Receives $20 Million Grant for Stroke Clinical Trial

ACTIsSIMA trial will assess safety and efficacy of stem cell product in patients with chronic motor impairments resulting from ischemic stroke

SanBio Receives $20 Million Grant for Stroke Clinical Trial

July 12, 2017 — SanBio Inc. recently announced it has been awarded a $20 million grant from the California Institute of Regenerative Medicine (CIRM) in support of its Phase 2b clinical trial for the treatment of chronic stroke (ACTIsSIMA), jointly sponsored with Sunovion Pharmaceuticals Inc.

CIRM is an agency of the State of California formed to accelerate the progress of regenerative medicine through a highly competitive grant program. Prospective grants are evaluated by an independent panel of the nation's top experts in regenerative medicine, as well as medical authorities on neurological disorders. The evaluation of this stroke program received CIRM's highest ranking of 1.

Stroke is the leading cause of acquired disability in the United States. Many patients suffer from permanent loss of function. After the first six months, the possibility for further recovery through traditional therapies is minimal. Sufferers from stroke disability impose a significant burden on the health care system.

“Today the CIRM Board approved two very different methods, using different kinds of stem cells, to address this need,” said Maria Millan, M.D., interim CEO and president of the agency. “By funding multiple shots on goal we believe that we have a better chance of finding a way to repair the damage caused by stroke and give people a better quality of life.”

The ACTIsSIMA (Allogeneic Cell Therapy for Ischemic Stroke to Improve Motor Abilities) clinical trial studies the safety and efficacy of SanBio’s proprietary cell-based product, SB623, in patients with chronic motor impairments resulting from ischemic stroke. Enrollment for the ACTIsSIMA study is expected to be complete in March 2018. Patients will be monitored for 12 months, with results reported in 2019. This trial follows its Phase 1/2a study, the results of which were reported in the journal Stroke last year.1

For more information: www.sanbio.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init